% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{MartinoAdami:285023,
      author       = {Martino-Adami, Pamela V and Jessen, Frank and Brosseron,
                      Frederic and Bewernick, Bettina and Domschke, Katharina and
                      Luppa, Melanie and Wagner, Michael and Peters, Oliver and
                      Frölich, Lutz and Riedel-Heller, Steffi and Schramm,
                      Elisabeth and Ramirez, Alfredo and Dafsari, Forugh S},
      title        = {{E}xploring blood-based biomarkers in late-life depression:
                      {C}orrelates of psychotherapeutic treatment outcomes.},
      journal      = {European psychiatry},
      volume       = {69},
      number       = {1},
      issn         = {0924-9338},
      address      = {Cambridge},
      publisher    = {Cambridge University Press},
      reportid     = {DZNE-2026-00148},
      pages        = {e18},
      year         = {2026},
      abstract     = {Major depressive disorder is a prevalent and debilitating
                      mental health condition contributing to a growing global
                      burden. Late-life depression (LLD), affecting individuals
                      over 60 years of age, is further associated with elevated
                      risks for cardiovascular diseases, cognitive decline, and
                      dementia. Treatment responses vary widely, potentially due
                      to underlying neurodegeneration and cellular senescence. We
                      aimed to explore blood-based biomarkers related to
                      Alzheimer's disease and senescence-associated secretory
                      phenotype (SASP) proteins, seeking to identify biological
                      underpinnings of LLD and their association with response to
                      psychotherapy.We performed a secondary analysis of the
                      Cognitive Behavioral Therapy for Late-Life Depression
                      (CBTlate) trial in 228 participants aged 60 years and older
                      with a diagnosis of LLD. Depression trajectories were
                      compared using clustering. In participants with available
                      plasma samples, biomarker data were generated post hoc. We
                      assessed associations between biomarkers and depression
                      trajectories, biomarker dynamics, and their ability to
                      predict treatment response.Two depression trajectories were
                      identified: persistently high stable Geriatric Depression
                      Scale (GDS) scores (hsGDS) and decreasing scores over time
                      (dGDS). The hsGDS group had more severe baseline depression
                      (p = 2.88 × 10-6), anxiety (p = 4.39 × 10-4), and sleep
                      disorders (p = 1.09 × 10-3), and was more likely to have a
                      history of major depression (p = 0.01) and mild cognitive
                      impairment (p = 0.01). Biomarker analysis revealed elevated
                      baseline plasma neurofilament light chain (NfL, p = 2.51 ×
                      10-2) and reduced C-X-C Motif Chemokine Ligand 5 (CXCL5, p =
                      2.83 × 10-2) in the hsGDS group. Including CXCL5 in
                      predictive models improved trajectory differentiation (p =
                      3.94 × 10-3).Cellular aging biomarkers like CXCL5 may
                      improve understanding of LLD and guide personalized
                      therapeutic interventions.},
      keywords     = {Humans / Biomarkers: blood / Aged / Male / Female / Major
                      Depressive Disorder: therapy / Major Depressive Disorder:
                      blood / Middle Aged / Cognitive Behavioral Therapy / Aged,
                      80 and over / blood-based biomarkers (Other) / cellular
                      senescence (Other) / late-life depression (Other) /
                      neurodegeneration (Other) / psychotherapeutic treatment
                      outcome (Other) / Biomarkers (NLM Chemicals)},
      cin          = {AG Jessen / AG Heneka / Patient Studies (Bonn) / AG Wagner},
      ddc          = {610},
      cid          = {I:(DE-2719)1011102 / I:(DE-2719)1011303 /
                      I:(DE-2719)1011101 / I:(DE-2719)1011201},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41572662},
      doi          = {10.1192/j.eurpsy.2026.10153},
      url          = {https://pub.dzne.de/record/285023},
}